Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

Supplements like GetSimpli Oral Semaglutide tend to be most effective when used in conjunction with a balanced diet and regular exercise. While semaglutide is a powerful tool for weight loss and ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

Getting skinny on weight loss meds takes a fat wad of cash ... appetite-suppressing medications, semaglutide is the active ingredient in anti-obesity jabs like Wegovy, and in the anti-diabetes ...

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...